Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042963 (
vomiting
)
31,883
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Between June, 1987 and December, 1993, ten patients with solitary kidney after total nephroureterectomy for advanced upper urothelial transitional cell carcinoma were treated with chemotherapy (M-VAC or modified M-VAC). This series comprised 6 males and 4 females between 27 and 81 years of age (mean age: 58.5 years). The site of primary lesions was the renal pelvis in one case, ureter in 5 and renal pelvis and ureter in 4. Histologically, these extripated tumors were all identified as transitional cell carcinoma, the stage being
pT3
and pT4 in 9 and grade being G3 in 8 of the 10 patients. Among the 13 cases including the 3 cases of recurrence after first line chemotherapy, 7 had lesions suitable for the evaluation. Two of the 7 cases achieved complete response and four achieved partial response, resulting in an 86% response rate. Of the 10 patients, 4 died of metastasis of carcinoma and the others are still alive. The average period after operation among 10 patients was 25 months. Side effects related to this chemotherapy were as follows: general fatigue, nausea or
vomiting
and alopecia 100%, leucocytepenia (< or = 1,000/mm3) 23%, anemia (RBC < or = 250 x 10(4)/mm3) 62%, thrombocytopenia (< or = 5 x 10(4)/mm3) 46%. However, nephrotoxicity in spite of solitary kidney was not noticed in any patients. From our experience, we suggest that M-VAC or modified M-VAC chemotherapy are safe against patients with a solitary kidney after nephroureterectomy for advanced transitional cell carcinoma of the upper urinary tract.
...
PMID:[Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma]. 774 Oct 70
The patient was a 57-year-old man diagnosed with cancer of the pancreatic head. After treatment by heavy ion beam therapy, pylorus-preserving pancreatoduodenectomy was performed. The tumor was
pT3
, pN0, pM0, stage IIA. Sixteen months after the surgery, the patient was admitted to the hospital because he was
vomiting
blood. Hemorrhaging caused by failure of the cut end of the gastroduodenal artery into the elevated jejunum was confirmed by angiogram, and the hemorrhaging could be stopped by a transcatheter arterial embolization operation. Twenty-four months after surgery, the patient was readmitted because he was once again
vomiting
blood. Hemorrhaging from the elevated jejunum was suspected by hemorrhagic scintigram, but the source could not be identified on further examination, and the choice of treatment was difficult. The patient died on the 9th day after admittance to the hospital. Even on examination at autopsy, the source of the hemorrhaging could not be identified. No recurrence of cancer could be found. This has proven to be a perplexing case, in that hemorrhaging from the end of the routinely cut gastroduodenal artery occurred 16 and 24 months after heavy ion beam therapy and pylorus-preserving pancreatoduodenectomy for pancreatic cancer.
...
PMID:Late hemorrhage after pancreatoduodenectomy and heavy ion beam therapy. 1752 Feb 13
A woman in her sixties underwent total gastrectomy for gastric cancer. The pathological diagnosis was
pT3
, pN3, sH0, pCY0, sP0, sM0, fStage IV. Chemotherapy with S-1 was used after surgical treatment. Because a CT scan after three courses chemotherapy showed the paraaortic lymph nodes swelling, combination chemotherapy with S-1 and docetaxel was used as a second-line chemotherapy. When the CT scan after 8 courses of this combination chemotherapy revealed multiple liver metastases, the chemotherapy was changed to CPT-11 monotherapy and paclitaxel monotherapy as the third-and fourth-line chemotherapy, respectively. In spite of those chemotherapies, the metastatic disease progressed, and therefore, combination chemotherapy with S-1 and CDDP was used as the fifth-line chemotherapy. After 6 courses of this treatment, serum CEA and CA19-9 levels dropped into the normal range. Multiple liver metastases were markedly reduced, and were considered as a partial response(PR). The patient is still alive, maintaining the effect of PR for 17 months without any adverse effects except appetite loss and
vomiting
of grade 2.
...
PMID:[A case of gastric cancer with liver metastasis had a good reaction to S-1/CDDP chemotherapy after S-1 chemotherapy was ineffective]. 2199 69